Clearmind Medicine Inc. (CMND) Form 6-K — Sep 1, 2026
Clearmind Medicine (Nasdaq: CMND) announced the initiation of Phase IIa, the next stage of its double-blind, placebo-controlled Phase I/IIa trial of CMND-100 for alcohol use disorder, with six patients enrolled to date — three at Tel Aviv Sourasky Medical Center and three at Hadassah Medical Center in Jerusalem. The milestone follows successful completion of the trial's initial safety part in healthy volunteers and a prior positive review by an independent Data and Safety Monitoring Board, enabling progression into multiple dosing in healthy volunteers and single dosing in AUD patients.
Key figures
- Trial Design
- four-part Phase I/IIa, double-blind, placebo-controlled
- Granted Patents
- 32
- Patent Families
- 19
- Patients Enrolled To Date
- 6
- Part CEnrollment Progress
- one-third of Part C enrolled
- Patients Enrolled At TASMC
- 3
- Patients Enrolled At Hadassah
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.